haloperidol has been researched along with alprazolam in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.11) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Barbee, JG; Freed, CR; Mancuso, DM; Todorov, AA | 1 |
| Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J | 1 |
| Cagiano, R; Cuomo, V; De Salvia, MA; Maselli, MA; Racagni, G; Renna, G | 1 |
| Kahn, JP; Klein, DF; Puertollano, M; Schane, MD | 1 |
| Jordan, J | 1 |
| Monfort, JC | 1 |
| Benfield, WR; Christensen, DB | 1 |
| Hijzen, TH; Joordens, RJ; Olivier, B | 1 |
| Greenberg, MI; Hendrickson, RG; Morocco, AP | 1 |
| Krzek, J; Maślanka, A; Szlósarczyk, M; Wach, K; Żmudzki, P | 1 |
1 review(s) available for haloperidol and alprazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for haloperidol and alprazolam
| Article | Year |
|---|---|
Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia.
Topics: Adult; Alprazolam; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Emergencies; Emergency Services, Psychiatric; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1992 |
Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.
Topics: Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antipsychotic Agents; Behavioral Symptoms; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Humans; Male; Nursing Homes | 1998 |
24 other study(ies) available for haloperidol and alprazolam
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Topics: Adult; Alprazolam; Antipsychotic Agents; Basal Ganglia Diseases; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1989 |
Ultrasonic vocalization in response to unavoidable aversive stimuli in rats: effects of benzodiazepines.
Topics: Alprazolam; Animals; Benzodiazepines; Desipramine; Diazepam; Electroshock; Flumazenil; Haloperidol; Male; Rats; Rats, Inbred Strains; Ultrasonics; Vocalization, Animal | 1988 |
Schizophrenia, panic anxiety, and alprazolam.
Topics: Adult; Alprazolam; Anxiety Disorders; Drug Therapy, Combination; Fear; Haloperidol; Humans; Male; Panic; Schizophrenia | 1987 |
Use of a revised version of the psychotropic medication efficacy graph.
Topics: Adult; Alprazolam; Haloperidol; Humans; Intellectual Disability; Male; Neurocognitive Disorders; Personality Disorders; Treatment Outcome | 1994 |
Alprazolam in the emergency treatment of schizophrenia.
Topics: Alprazolam; Drug Therapy, Combination; Emergencies; Haloperidol; Humans; Schizophrenia | 1993 |
The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Central Nervous System Depressants; Chlordiazepoxide; Ethanol; Fear; GABA-A Receptor Agonists; Haloperidol; Male; Rats; Rats, Wistar; Reflex, Startle; Sensitivity and Specificity; Strychnine | 1998 |
Acute dystonic reactions to "street Xanax".
Topics: Adolescent; Adult; Alprazolam; Child; Dystonia; Female; Haloperidol; Humans; Illicit Drugs; Male | 2002 |
Dependence of the kinetic and thermodynamic parameters on hydrophilic-lipophilic character of alprazolam, clonazepam, diazepam, doxepin and haloperidol in alkaline environment.
Topics: Alprazolam; Clonazepam; Diazepam; Doxepin; Drug Stability; Haloperidol; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kinetics; Thermodynamics | 2013 |